Health

  • February 24, 2026

    Clark Hill Faces DQ Bid In NJ Health Noncompete Fight

    Clark Hill PLC is facing a disqualification bid in New Jersey federal court from a health consulting company arguing the firm is unethically seeking to take sides in a dispute between two codefendants.

  • February 24, 2026

    AstraZeneca Drug Price Challenge Falls Short In Hawaii

    A federal judge in Hawaii temporarily upheld the state's law that prevents drug manufacturers from blocking safety-net hospitals from contracting with an unlimited number of outside pharmacies to dispense discounted prescription drugs under the 340B Drug Discount Program. 

  • February 24, 2026

    Medtronic's Diabetes Spinoff MiniMed Seeks $742M IPO

    Diabetes-focused MiniMed Group on Tuesday launched plans to go public by raising an estimated $742 million in an initial public offering, a move that is part of a previously announced plan by parent company Medtronic to spin its diabetes business into an independent public company.

  • February 24, 2026

    8th Circ. Won't Revive Iowa Pathology Lab's Antitrust Claims

    The Eighth Circuit has affirmed a lower court ruling that tossed a case accusing Iowa Pathology Associates of monopolizing pathology services in central Iowa, finding the rival never explained why doctors can't use labs that are located further away.

  • February 23, 2026

    FedEx, Bausch, Other Cos. Join Race For Tariff Refunds

    FedEx, Bausch & Lomb and L'Oreal are among the companies that raced to the U.S. Court of International Trade on Monday seeking full refunds of the trade duties they paid as a result of the 2025 tariffs that President Donald Trump illegally imposed under the International Emergency Economic Powers Act.

  • February 23, 2026

    DC Circ. Talks Sharks, Moats In Vertex HHS Kickback Appeal

    Sharks and moats were top of mind Monday morning for one judge on the D.C. Circuit, as gene therapy drugmaker Vertex Pharmaceuticals attempted to convince the court that its fertility preservation program does not violate the Anti-Kickback Statute.

  • February 23, 2026

    Zynex Faces Securities Suit Following Arrest Of Former Execs

    After being arrested last month on charges of securities fraud and conspiracy, the former CEO and ex-chief compliance officer of bankrupt medical device maker Zynex have been hit with a securities class action that alleges they and others caused the company to engage in fraudulent billing practices that inflated its stock price and led to investor losses once the truth came to light.

  • February 23, 2026

    Fla. Hospital Blames UnitedHealth In Cyberattack Suit

    A Florida hospital sued UnitedHealth Group Inc. and several subsidiaries in Georgia federal court on Friday, saying they didn't live up to their contractual obligations when a 2024 cyberattack left the hospital unable to process payments for weeks.

  • February 23, 2026

    Philly-Area Fertility Clinic Settles Patient's Acid Burn Suit

    A woman who sued a fertility clinic for allegedly mistakenly injecting her uterine cavity with acid, which she said caused her to suffer second-degree burns, has settled her lawsuit against the clinic for an undisclosed amount.

  • February 23, 2026

    Disability Group Says Mich. Agency Isn't Honoring Judgment

    A disability advocacy group asked a Michigan federal judge on Monday to order a county mental health agency to explain why it should not be held in civil contempt, saying the agency refused to follow new Medicaid budgeting rules that were adopted as part of a court-approved settlement.

  • February 23, 2026

    SEC Says PPE Distributor Fabricated Pandemic-Era Deal

    The U.S. Securities and Exchange Commission filed a suit Monday accusing the CEO and consultant of a consumer goods company of artificially inflating the company's share price by nearly 200% by disseminating a false press release touting $10 million in orders for health supplies at the beginning of the COVID-19 pandemic.

  • February 23, 2026

    Asthma Biotech Generate Biomedicines Eyes $400M IPO

    Asthma-focused biotech firm Generate Biomedicines on Monday filed plans with U.S. regulators to raise around $400 million in its initial public offering led by Goodwin Procter LLP and Latham & Watkins LLP.

  • February 23, 2026

    Analyst Who Claimed She Was Fired For Needing Sleep Settles

    A New Jersey woman who claimed she was fired by Centerview Partners after disclosing she needed consistent sleep to manage a health disorder settled her case against the investment bank ahead of a jury trial in New York federal court, the bank said Monday.

  • February 23, 2026

    Pittsburgh Law Firm Hit With Class Claims Over Data Breach

    A Pittsburgh-based law firm has been hit with proposed class claims alleging it failed to protect clients' private information, which was compromised by a data breach in May.

  • February 23, 2026

    NJ Watchdog Takes File Fight In Hospital Row To 3rd Circ.

    A New Jersey watchdog will take its bid to shield investigative files from discovery in a hospital's antitrust suit to the Third Circuit, according to a court notice.

  • February 23, 2026

    Hims & Hers Misleads With GLP-1 Claims In Ads, Court Told

    A class of GLP-1 patients claim that telehealth company Hims & Hers falsely advertised its compounded injections as made with "the same active ingredient" as weight loss drugs Ozempic and Wegovy despite containing other key ingredients, according to a suit filed in Illinois federal court. 

  • February 23, 2026

    Ropes, Wilson Sonsini Guide Gilead's $7.8B Arcellx Buy

    Gilead Sciences Inc. announced Monday that it has agreed to acquire clinical-stage biotechnology company Arcellx Inc. for $115 per share in cash plus one contingent value right worth $5 per share, reflecting an implied equity value of $7.8 billion.

  • February 23, 2026

    Kirkland, Jones Day Build $1.1B Hospice Take-Private Deal

    Home health and hospice provider Enhabit Inc., advised by Jones Day, on Monday unveiled plans to go private following a sale to middle market private equity firm Kinderhook Industries LLC, led by Kirkland & Ellis LLP, in an all-cash deal valued at roughly $1.1 billion.

  • February 23, 2026

    High Court Won't Wade Into Doctor's Retaliation Suit

    The U.S. Supreme Court declined Monday to consider reviving a doctor's retaliation suit claiming a New York City-area hospital system forced his exit for raising patient safety concerns, despite his argument that the healthcare provider had withheld an email that supported his case.

  • February 20, 2026

    Class Attys Allege Lead Counsel Is Hoarding $75M Sutter Fees

    Schneider Wallace Cottrell Kim LLP has urged a California federal magistrate judge to enforce the $75.4 million fee award in Sutter Health's $228.5 million deal resolving a decade-long antitrust fight, arguing lead counsel Constantine Cannon LLP "unilaterally" and "arbitrarily" cut SWCK's fees by nearly $800,000 while boosting its own.

  • February 20, 2026

    Texas AG Sues Retailer Over Chest Binder Sales To Youth

    The Texas attorney general on Friday hit an online retailer with a suit alleging that it sells chest binders as undergarments to young people, in what appears to be the first suit in the state targeted at a product used in gender-affirming care.

  • February 20, 2026

    Dallas Jury Finds Ex-NFL Player Ran $328M Medicare Scheme

    A federal jury in Dallas has found that former NFL player and Texas laboratory owner Keith Gray orchestrated a $328 million fraud scheme involving billing for cardiovascular genetic testing, federal prosecutors said Thursday.

  • February 20, 2026

    Fertility Doctors Beat Patient's Embryo Loss Case

    A Connecticut woman waited too long to sue her fertility doctors over the loss of her frozen embryos after treatments in 2005 and 2006, a state court judge ruled Thursday, granting judgment to the doctors.

  • February 20, 2026

    Fed. Circ. Unwinds Ineligibility Ruling For Gene Therapy IP

    The Federal Circuit on Friday saved Regenxbio and the University of Pennsylvania's gene therapy patent, finding that splicing together genes from different organisms results in a molecule that is "markedly different from anything occurring in nature," rendering the therapy patent eligible. 

  • February 20, 2026

    DOJ Says Ohio Health System's Contracts Violate Antitrust

    The U.S. Department of Justice and Ohio's attorney general's office sued OhioHealth Corp. Friday in federal court, accusing the healthcare system of using contractual restrictions to block insurers from offering plans that include lower-cost rivals.

Expert Analysis

  • AI-Generated Doc Ruling Guides Attys On Privilege Risks

    Author Photo

    A New York federal court's ruling, in U.S. v. Heppner, that documents created by a defendant using an artificial intelligence tool were not privileged, can serve as a guide to attorneys for retaining attorney-client or work-product privilege over client documents created with AI, say attorneys at Sher Tremonte.

  • To Survive FCA Actions, Small Cos. Must Take Offensive Steps

    Author Photo

    A fumbled response to False Claims Act allegations can doom lower-middle-market businesses, and with FCA enforcement hitting record levels for two years, smaller companies must have offensive strategies ready that focus their limited resources on defeating civil qui tam and federal criminal actions, says Derrelle Janey at Olshan Frome.

  • The Law Firm Merger Diaries: Leadership Strategy After Day 1

    Author Photo

    For law firm leaders, ensuring a newly combined law firm lives up to its promise, both in its first days of operation and well after, includes tough decisions, clear and specific communication, and cheerleading, says Peter Michaud at Ballard Spahr.

  • How US Liability Law Is Becoming The Primary Regulator Of AI

    Author Photo

    Comprehensive federal AI regulation remains fragmented and uncertain — but U.S. courts, applying long-standing doctrines of liability and responsibility, are actively shaping how AI systems are designed, deployed and governed, and companies are aligning their AI practices because courts may hold them accountable if they do not, says Alexander Lima at Wesco International.

  • Record FCA Recoveries Signal Intensified Healthcare Focus

    Author Photo

    In its recently released False Claims Act statistics, the U.S. government's emphasis on record healthcare recoveries and government-initiated healthcare matters last year indicates robust enforcement ahead, though the administration's focus on current policy objectives also extends beyond the healthcare sector, say attorneys at Epstein Becker.

  • Fed. Circ. In Jan.: On The Validity Of Expert Testimony

    Author Photo

    The Federal Circuit's recent decision in Barry v. DePuy, addressing whether expert testimony is admissible even if it does not strictly adhere to the court's claim construction, suggests that exclusion via a Daubert motion is appropriate only when the line to improper testimony is clearly crossed, say attorneys at Knobbe Martens.

  • Methods For Challenging State Civil Investigative Demands

    Author Photo

    Ongoing challenges to enforcement actions underscore the uphill battle businesses face in arguing that a state investigation is prohibited by federal law, but when properly deployed, these arguments present a viable strategy to resist civil investigative demands issued by state attorneys general, say attorneys at Troutman Pepper.

  • Calif.'s Civility Push Shows Why Professionalism Is Vital

    Author Photo

    The California Bar’s campaign against discourteous behavior by attorneys, including a newly required annual civility oath, reflects a growing concern among states that professionalism in law needs shoring up — and recognizes that maintaining composure even when stressed is key to both succeeding professionally and maintaining faith in the legal system, says Lucy Wang at Hinshaw.

  • A Potential Shift In FDA's Approach To Drug Trial Design

    Author Photo

    Recent guidance released by the U.S. Food and Drug Administration clarifying how Bayesian approaches — which combine prior knowledge with new data — may be used in clinical trials reflects the agency's continued interest in innovative trial designs that may accelerate drug approvals, say attorneys at Alston & Bird.

  • Opinion

    SNAP Rule Confusion Risks A Compliance Crisis

    Author Photo

    Recent Supplemental Nutrition Assistance Program food restriction waivers pose a compliance crisis for legal practitioners advising food retailers, amid higher costs and lack of a coherent national standard, says Tyson-Lord Gray at Yeshiva University’s Benjamin N. Cardozo School of Law.

  • Series

    Trivia Competition Makes Me A Better Lawyer

    Author Photo

    Playing trivia taught me to quickly absorb information and recognize when I've learned what I'm expected to know, training me in the crucial skills needed to be a good attorney, and reminding me to be gracious in defeat, says Jonah Knobler at Patterson Belknap.

  • What FDA Guidance Means For Future Of Health Software

    Author Photo

    Two significant final guidance documents released by the U.S. Food and Drug Administration last month reflect a targeted effort to ease innovation friction around specific areas, including singular clinical decision support recommendations and sensor-based wearables, while maintaining established regulatory boundaries, say attorneys at Covington.

  • Opinion

    Federal Preemption In AI And Robotics Is Essential

    Author Photo

    Federal preemption offers a unified front at a decisive moment that is essential for safeguarding America's economic edge in artificial intelligence and robotics against global rivals, harnessing trillions of dollars in potential, securing high-skilled jobs through human augmentation, and defending technological sovereignty, says Steven Weisburd at Shook Hardy.

  • Series

    Law School's Missed Lessons: What Cross-Selling Truly Takes

    Author Photo

    Early-career attorneys may struggle to introduce clients to practitioners in other specialties, but cross-selling becomes easier once they know why it’s vital to their first years of practice, which mistakes to avoid and how to anticipate clients' needs, say attorneys at Moses & Singer.

  • How State FCA Activity May Affect Civil Fraud Enforcement

    Author Photo

    A growing trend of state attorneys general enforcing their False Claims Act analogues independently of the U.S. Department of Justice carries potential repercussions for civil fraud enforcement and qui tam litigation considerations, say Li Yu at Bernstein Litowitz, Ellen London at London & Naor and Gwen Stamper at Vogel Slade.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here